Moderna wins patent lawsuit against BioNTech/Pfizer

Pfizer convinces US Patent Office to cancel two Moderna COVID-19 vaccine patents
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U.S. Patent Office tribunal that two patents Moderna accused them of infringing were invalid.
Pfizer and BioNTech violated COVID-19 vaccine patent held by Moderna, German court rules
The court said Pfizer and BioNTech would have to provide information on earnings derived from the use of the patent and that they owe Moderna appropriate compensation
Pfizer and BioNTech COVID vaccine broke patent — German court
FRANKFURT - A German court found Wednesday that American pharmaceutical giant Pfizer and German firm BioNTech violated a patent to make their COVID-19 vaccine.Siding with Moderna, an American pharmaceutical firm that brought the case,
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna. In a statement, the court in the city of Duesseldorf said that Pfizer and BioNTech would have to provide information on earnings derived from the use of the patent and that they owe Moderna appropriate compensation,
Moderna wins patent lawsuit against BioNTech/Pfizer in German court
A German court ruled on Wednesday that BioNTech and Pfizer violated a Covid-19 patent held by rival Moderna. US-based Moderna had asserted claims for information and damages for infringement of its patent rights in the development of the Covid-19 vaccine.
Moderna (MRNA) Stock Climbs as CEO and Director Make Strategic Insider Purchases
Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...
Why You Shouldn’t Be Buying MRNA Stock At $35
Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...
Moderna Eyes 2027 Launch for Cancer Vaccine Developed With Merck
Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...
S&P 500 Gains and Losses Today: Moderna Stock Pops as Execs Buy Shares, Express Cancer Vaccine Optimism
The S&P 500 advanced 1.1% on Wednesday, March 5, as the White House announced it would delay tariffs affecting U.S.
Trump administration weighs pulling funding for Moderna bird flu vaccine, Bloomberg News reports
U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird ...
FiercePharma1d
Arbutus, Genevant expand COVID patent feud with Moderna with 5 international lawsuits
Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with ...
PMLiVE21h
Moderna’s RSV vaccine mRESVIA granted MHRA approval to protect older adults
Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the Medicines and Healthcare products ...
Moderna, Inc. (MRNA) TD Cowen 45th Annual Health Care Conference
Moderna, Inc. ( NASDAQ: MRNA) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET All right, well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.
Can Moderna's Aggressive Cost Cuts Help Turn Things Around for Its Stock?
For now, Moderna may be a good stock to put on a watch list, but it's likely too risky and volatile for the vast majority of ...